Additional file 1 of Efficacy and safety of mesenchymal stem cell therapy in liver cirrhosis: a systematic review and meta-analysis

Additional file 1. Figure S1: Forest plot of secondary indicators: (A): ALT levels (B): AST levels. (C): TBIL levels. (D): INR levels. Figure S2: Time subgroup of ALT levels. Figure S3: Time subgroup of AST levels. Figure S4: Time subgroup of TBIL levels

Additional file 1 of Screening of placenta accreta spectrum disorder using maternal serum biomarkers and clinical indicators: a case–control study

Additional file 1: Table S1. Serum biomarkers measured and the commercial ELISA kits used. Table S2. Primers for RT-QPCR. Table S3. Alterations in serum levels of cytokines and proteins between cases and controls in the screening group of Cohort one. Table S4. Confirmation of selected serum biomarkers for PAS screening in the validation group of Cohort one. Table S5. Specificity analysis of selected serum biomarkers for PAS screening the testing group of Cohort one. Table S6. Analysis of protein expression levels on human placenta